SCHEMBL6922828

SCHEMBL6922828

O=c1c2ccc(-c3ccccn3)cc2nc2n1C1CCN(CC1)C2

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 1/20 0.38
GAA P10253 1/20 0.38
ALOX15 P16050 1/20 0.38
CYP3A4 P08684 1/20 0.38
DHODH Q02127 1/20 0.37
PRMT5 O14744 2/20 0.37
WDR77 Q9BQA1 1/20 0.37
USP30 Q70CQ3 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
ATM Q13315 1/20 0.36
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36
TDP1 Q9NUW8 1/20 0.36
GSK3B P49841 1/20 0.36
DYRK1A Q13627 1/20 0.36
TGFBR1 P36897 1/20 0.35
ABL1 P00519 1/20 0.35
METAP2 P50579 1/20 0.35
DRD2 P14416 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14238872 0.94 CYP2C9 (0.39) CYP2C9GAAALOX15CYP3A4DHODH
SCHEMBL6922215 0.82 TGFBR1 (0.43) GAAALOX15CYP3A4DHODHPRMT5
SCHEMBL12041843 0.79 POLB (0.45) GAAALOX15NPC1RAB9ATDP1
SCHEMBL6921512 0.79 CYP3A4 (0.42) CYP3A4DHODHPRMT5WDR77NPC1
SCHEMBL6920937 0.78 TGFBR1 (0.51) CYP3A4TGFBR1
SCHEMBL6922279 0.77 NPC1 (0.39) GAAALOX15CYP3A4DHODHNPC1
SCHEMBL6922696 0.77 CYP3A4 (0.41) CYP3A4DHODHPRMT5WDR77NPC1
SCHEMBL6922143 0.77 CYP3A4 (0.40) GAAALOX15CYP3A4MEN1KMT2A
SCHEMBL6922743 0.77 ALOX15 (0.39) GAAALOX15MEN1KMT2AATM
SCHEMBL6922431 0.76 NPC1 (0.39) CYP2C9GAAALOX15CYP3A4USP30

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110319380-A1 Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof SUNOVION PHARMACEUTICALS INC. (US) 2011-12-29 US disclosed
WO-2011075699-A2 COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF SUNOVION PHARMACEUTICALS INC. (US) 2011-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110319380-A1 Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof GRM5, GRM2, GRM1 CYP2C9 4663/4885GAA 1294/4885ALOX15 919/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.